Latham & Watkins LLP represents Jefferies LLC and Leerink Partners LLC acting as placement agents in the financing. Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global...
Structure Therapeutics’ US$300 Million Private Placement Equity Financing
HilleVax’s €100 Million Common Stock Public Offering
Latham & Watkins Advises HilleVax on Pricing of Public Offering of Common Stock. HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Crinetics Pharmaceuticals’ $350 Million Public Offering of Common Stock
Latham & Watkins advised Crinetics, and Cooley advised the underwriters on the offering. Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced the pricing of an upsized underwritten public...
Gossamer Bio’s $212 Million Private Placement Financing
Latham & Watkins represented Gossamer Bio in the transaction. Gossamer Bio, Inc. (Nasdaq: GOSS) announced that it has entered into a securities purchase agreement with institutional...
Janux Therapeutics’ $60 Million Offering of Common Stock and Pre-Funded Warrants
Cooley advised Janux, and Latham & Watkins advised the underwriter on the offering. Janux Therapeutics, Inc. (Nasdaq: JANX) has announced the pricing of an underwritten offering of...
Iovance Biotherapeutics’ $150 Million Common Stock Public Offering
DLA Piper advised Iovance, and Latham & Watkins advised the underwriters. Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) announced the pricing of an underwritten public offering of 20,000,000 shares...
Phathom Pharmaceuticals’ $130 Million Public Offering of Common Stock
Latham & Watkins advises Phathom Pharmaceuticals in pricing of US$130 million public offering of common stock. Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and...
eFFECTOR Therapeutics’ $7.5 Million Registered Direct Offering
Latham & Watkins advises eFFECTOR Therapeutics in US$7.5 million registered direct offering. eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs)...
Icosavax’s $67.8 Million Registered Direct Offering of Common Stock
Latham & Watkins advised Icosavax on the offering. Icosavax, Inc. (Nasdaq: ICVX) has announced that it has entered into a securities purchase agreement with investors in a...
Reneo Pharmaceuticals’ Common Stock Offering
Cooley advised Reneo, and Latham & Watkins advised the underwriters and placement agents. Reneo Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of...
Merck’s Acquisition of Prometheus Biosciences
Paul, Weiss, Rifkind, Wharton & Garrison represented Merck, Latham & Watkins represented Prometheus, Skadden represented the financial advisors on the deal. Prometheus Biosciences, Inc. have entered...
Travere Therapeutics’ $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Cooley advises Travere Therapeutics, and Latham & Watkins advises the underwriters. Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced the pricing of an underwritten public offering of...